Compare PACK & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PACK | OCGN |
|---|---|---|
| Founded | 1972 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.2M | 474.8M |
| IPO Year | 2017 | 2014 |
| Metric | PACK | OCGN |
|---|---|---|
| Price | $3.73 | $0.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $7.08 | ★ $12.17 |
| AVG Volume (30 Days) | 504.1K | ★ 7.3M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $395,000,000.00 | N/A |
| Revenue This Year | $9.87 | $12.33 |
| Revenue Next Year | $9.00 | $10.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.08 | N/A |
| 52 Week Low | $3.22 | $0.96 |
| 52 Week High | $7.81 | $2.73 |
| Indicator | PACK | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 30.24 | 33.08 |
| Support Level | $3.31 | N/A |
| Resistance Level | $3.82 | $1.93 |
| Average True Range (ATR) | 0.18 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 4.68 | 9.10 |
Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").